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Abstract 
Steroid Resistant Nephrotic Syndrome (SRNS) in children and young adults has differing 
aetiologies with monogenic disease accounting for 2.9-30% in selected series.  
We aimed, using whole exome sequencing, to stratify a national population of SRNS children 
into monogenic and non-monogenic forms, and further define those groups by detailed 
phenotypic analysis 
Paedatric SRNS patients were collected via a national UK Renal Registry (RaDaR). Whole exome 
sequencing (WES) was performed on 187 patients, of which 12% had a positive family history. 
Analysis focused on the 53 genes currently known to be associated with NS. Genetic findings 
were correlated with individual case disease characteristics. 
Disease causing variants were detected in 26.2% of patients. Most occurred in the three most 
commonly SRNS associated genes: NPHS1, NPHS2 and WT1 but also in 14 other genes. Genotype 
did not always correlate with expected phenotype, e.g. mutations in OCRL, COL4A3 and DGKE, 
associated with specific syndromes, were detected in isolated renal disease. Analysis by 
primary/presumed vs. secondary steroid resistance revealed 30.8% monogenic disease in 
primary compared to 0% in secondary SRNS permitting further mechanistic stratification. 
Genetic SRNS progressed faster to end stage renal failure, with no documented disease 
recurrence post-transplantation within this cohort. Primary steroid resistance in which no gene 
mutation was identified had a 47.8% risk of recurrence  
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In this unbiased paediatric population, WES allowed screening of all current candidate genes. 
Together with deep phenotyping we propose that this is an effective tool for early identification 
of SRNS aetiology, yielding an evidence-based algorithm for clinical management. 
 
 
 
 
 
 
Introduction 
Nephrotic syndrome is a heterogeneous entity only recently divided into mechanistic 
categories.  Although population analyses have been limited in paediatric cohorts1-3, idiopathic 
nephrotic syndrome (INS) has an estimated incidence of around 2 - 5/100,000 children/year 
depending on ethnic background2. INS is currently classified into Steroid Sensitive (SSNS), or 
Steroid Resistant (SRNS), with at least 2.9-30% of SRNS cases (in series variably enriched for 
consanguineous disease or other phenotypes) now known to have an underlying Mendelian, 
genetic cause. A challenging subset of cases, considered to be immunologically mediated and 
caused by an as yet unidentified circulating factor(s) can present as secondary steroid 
resistance after initial steroid sensitivity.4 The most dramatic evidence of the presence of a 
‘circulating factor’ is rapid recurrence of nephrotic disease soon after kidney transplantation in 
40-60% of graft recipients with SRNS. 
Approximately 70% of children with idiopathic NS respond to steroids and other 
immunosuppression, whereas the remaining 30% are resistant to this therapy at the outset and 
have primary SRNS. Of the 70%, a further 20 to 30% of cases who initially have steroid sensitive 
disease become steroid resistant, termed secondary SRNS. Histological appearance has limited 
correlation to pathomechanism, but renal biopsy of SRNS generally shows focal segmental 
glomerulosclerosis (FSGS). There are currently no robust or reliable clinical indicators or 
biomarkers of response meaning that prediction of disease progression or response to 
medication cannot be clearly defined.  
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The question remains open whether SSNS and SRNS are on the same spectrum, or distinct 
entities. It has become apparent that up to 30% of patients with SRNS could have Mendelian 
disease caused by genetic mutation.5 Since the advent of next generation sequencing (NGS), the 
discovery and extent of these gene mutations has grown rapidly, though exact incidence, 
particularly within the above clinical subgroups, remains unclear. Table 1 lists the 53 genes 
currently associated with SRNS,.5-7 
 
To date, studies on patients with NS have been limited by the number of genes covered, cohort 
number, and/or selection of phenotype included. We hypothesised that by applying clinically 
relevant inclusion criteria (Table 2) to a comprehensive cohort, utilising whole exome coverage 
to screen for all currently known causative genes, we could identify the true incidence and 
range of genetic disease in an otherwise unbiased population more accurately. Furthermore, we 
hypothesised that combining clinical criteria, including age of onset and steroid responsiveness, 
to comprehensive gene testing, would help to stratify between immunological/circulating factor 
disease and genetic disease, and better predict recurrence risk post-transplantation. 
We screened the first 187 patients recruited to our national SRNS cohort, in an unbiased 
manner in order to understand the disease at the level of clinical presentation. The aim was to 
stratify for genetic vs ‘circulating factor disease’, and to determine whether this was linked to 
clinical predictability of disease progression, recurrence risk post-transplantation, and 
mechanistically targeted disease management. 
 
Results 
Cohort Characteristics and incidence of genetic disease 
The clinical details of the 187 cases screened are presented in Table 3, with more detailed 
phenotyping shown in Table S2.  
 
22/187 (12%) had familial disease, 164 were sporadic and 1 unknown (presumed sporadic).  
59% (13/22) of patients in the familial group and 22% (36/164) in the sporadic group, had an 
identified mutation or a variant likely to be disease causing.  The majority of familial patients 
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had a mutation in recessive, or dominant negative (WT1), genes (39 patients) and this group of 
patients had a trend towards an earlier age of onset compared to patients with a dominant gene 
mutation (10 patients) (Unpaired t test, two-tailed, P 0.07).   
69/187 (36.9%) had developed end stage renal failure. 54 cases had undergone renal 
transplantation, the other 15 cases were on peritoneal dialysis or haemodialysis at last follow 
up. The subgroup that had reached chronic kidney disease (CKD) stage 5 and had a genetic 
aetiology of disease had an earlier age of onset compared to CKD stage 5 cases with SRNS in 
whom gene mutations had not been identified (4.75 vs 6.28 years, P value 0.0082, unpaired t 
test). No such difference was observed between patients with primary/presumed and 
secondary steroid resistance (4.86 vs 5.64 years, P value 0.6321, unpaired t test). Recurrence of 
the disease was noted in 27.8% of the transplanted patients. The rate of recurrence in those 
with a genetic form was 0/25 transplants, and with non-genetic/unknown was 15/29 
transplants (51.7%) (Fisher's exact test, Two-sided, P<0.0001) 
This phenotypic analysis confirms that patients with an identified gene mutation are more likely 
to progress faster to end stage renal failure (Figure 1). In this cohort 59.8% of genetic and 
19.4% non-genetic/unknown SRNS patients reached CKD stage 5 within 4 years from diagnosis. 
The mean length of follow up for both patient groups was 7.6 years (min 1.00, max 18.03 years) 
and 6.2 years (min 0.58, max 16.55 years) respectively. 
 
Patients with a mutation in NPHS1 had an earlier mean age of onset than those with a mutation 
in NPHS2, 0.72 and 5.94 years respectively. 13 patients with congenital nephrotic syndrome 
(CNS) were found to have known or potential mutations in NPHS1, LAMB2 and WT1. 
 
Histopathological Findings 
A renal biopsy was undertaken in 181/187 (96.8%) patients within 3 months of their date of 
diagnosis (3 patients with congenital nephrotic syndrome (CNS) were not biopsied and 3 
patients’ results were not available). The majority of patients had focal segmental 
glomerulosclerosis (FSGS) (54.1%->98/181) or minimal change (MCD)  (23.8%->43/181) on 
biopsy however other variations (Table 3) were also reported. Biopsy reports did not correlate 
in any systematic manner with the genetic results identified. 
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Detailed Sequencing Results 
Exome sequencing was performed on 187 paediatric SRNS/FSGS patients. Variants that fulfilled 
the filtering criteria to be causative (supplementary data) were detected in 17/53 known SRNS 
genes in 49/187 patients, 26.2% of the complete cohort, (not including APOL1 risk G1 and G2 
alleles), as shown in Table 1. A list of pathogenic variants is shown in Table 4. Of these, we 
identified 32 novel/rare variants that have not previously been reported in the literature. They 
are in the following genes: NPHS1, NPHS2, ACTN4, TRPC6, MYO1E, COL4A3, DGKE, LMX1B, 
PODXL, OCRL, COL4A58, ADCK49,CRB210, NUP93 and NUP107. The most frequently mutated genes 
in our cohort were NPHS1, NPHS2 and WT1 and this comprised 61.2% (30/49) of genetic 
detection in our cohort.  Variants of unknown significance can be found in Table S3. 
 
Analysis of genetic cohort 
In total, 187 cases were sequenced, 96 male and 91 female, with a range of onset of NS between 
birth and 16 years (mean 5.6 years). No gender difference was observed between cases with a 
pathogenic gene variant identified and those without. Patients were grouped according to their 
age at onset of SRNS; the maximum prevalence occurred between 1-3 years old (51 cases) 
followed by 3-5 years old (34 cases). The highest proportion of genetic mutations was found in 
the 0-0.25 year group (13/15 or 87% of patients).  
 
Variants Discovered in Commonly Associated Genes 
In the < 2 years age group, NPHS1 mutations were most frequently detected variants, namely in 
14 patients with a mean age at onset of 0.72 years. Six novel likely disease-causing variants are 
described in Table 4. One of the sequenced patients (22) had congenital nephrotic syndrome 
(CNS) and a heterozygous mutation in NPHS1 p.Arg1160*, previously described in patients with 
a similar phenotype.11,12 There were no other novel/rare variants in exons and splice site 
regions identified in NPHS1 in this patient; however NGS analysis indicated the presence of a 
heterozygous deletion of exon 8. This deletion has subsequently been confirmed and 
investigated further by the use of bespoke custom designed MLPA probes. WT1 mutations were 
the second most frequent, and detected in 4 patients with a mean age of onset of 1.68 years.  
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NPHS2 gene mutations were the most commonly detected in the > 2 years age group: 12 
patients were found to have a known- or likely novel- disease causing variant with the mean age 
of onset of 5.94 years.  
Variants Detected in genes less frequently presenting in childhood. 
TRPC6 and ACTN4 may cause both familial and sporadic juvenile and adult onset SRNS. It has 
been previously noted that mutations in these genes can sometimes cause disease with early 
childhood onset.5,13-15 Patients 30 and 38 were diagnosed at 7 and 3 years respectively, and 
found to have TRPC6 mutations, and patient 29 was diagnosed at 12 years and had a novel 
ACTN4 mutation. All 3 patients were sporadic. 
We found several patients presenting overtly with SRNS, but associated with gene mutations 
usually linked to another renal phenotype. These were patient 33 with a DGKE mutation 
(usually atypical HUS), patient 44 with an OCRL mutation (usually Dent’s disease type 2), and 
patient 32 with a COL4A3 mutation (usually familial haematuria). Additional clinical details are 
presented within Supplemental data. 
Other less common genes found mutated in this cohort included 2 patients (21 and 39) with 
LMX1B mutations (one with no extra-renal involvement), one novel variant in PODXL (patient 
43), and 5 patients with the newly-described nucleoporin mutations, NUP93 and NUP107 
(patients 45-48), making this a considerable subset of mutations within the cohort (10.2%). 
Further clinical and genetic details of these patients are presented as Supplementary Data. 
 
APOL1 risk alleles 
Until recently APOL1 risk alleles (for accelerated kidney disease) were described only in adult 
patients of African descent. Recently, Anyaegbu and colleagues showed that effects of APOL1 
nephropathy can also be found in young patients.16 70% (130/187) of patients in our cohort are 
Caucasian whereas other ethnicities represented 30% (57/187). In our study, we found 3 
patients (50, 95 and 101) of African descent with either homozygous or a compound 
heterozygous APOL1 G1 and G2 risk variants. All 3 patients had presented before the age of 10 
years and did not have any known or likely pathogenic variants in the nephrotic genes.  
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Discussion 
This population-based exome sequencing approach has yielded several novel insights into 
SRNS. These include: the largest exome based study to date, and therefore the most accurate 
current incidence of monogenic disease, by taking into account all current genes implicated; An 
estimated incidence of circulating factor disease (CFD), based on clinical and genetic screening; 
The clinical utility of whole exome sequencing as the most relevant tool for screening in the 
rapidly evolving environment of monogenic SRNS; And a sufficiently sized population cohort 
from which to derive stratification based algorithms for clinical care 
As clinicians treating children with nephrotic syndrome, one of the major barriers to optimal 
care is the inability to predict disease course and target treatment appropriately at an early 
stage after diagnosis.  Stratifying patients by steroid sensitivity or resistance has been used 
effectively for many years.  The recognition over the past decade of an increasing number of 
genetic causes for paediatric and adult SRNS provides an opportunity for further stratification 
and potential for personalised medicine.  Using the data from the cohort presented here, which 
combines deep phenotyping with whole exome sequencing, we were able to explore how far we 
can stratify INS into genetic and circulating factor disease (CFD), with a potential proportion 
that can be placed outwith those groups.  
The data suggest that there are two distinct categories of genetic and of circulating factor 
disease, with a significant proportion remaining ‘unknown’ almost exclusively with the clinical 
characteristics of primary steroid resistance and negative for genetic testing. 
We have derived a clinically applicable working algorithm that firstly pinpoints the cohort likely 
to benefit from deep genetic analysis, the incidence of genetic disease in each subgroup of that 
cohort, and the broad range of genetic variation found. Further analyses include extracting 
recurrence risk post-transplantation and primary/secondary steroid resistance and correlating 
these clinical phenotypes with genotype.  
In order to ascertain which patients to screen by whole exome sequencing, we performed an 
initial stratification step (Table 2), whereby patients with a specific secondary diagnosis by 
clinical criteria (e.g. obesity/hypertension related glomerulopathy, diabetic nephropathy) 
and/or biopsy evidence (e.g. membranous nephropathy, MPGN) would highly likely not have an 
underlying monogenic disorder related to the genes we have tested. It is possible that our 
clinical inclusion criteria excluded some patients who would be found to have a monogenic 
disease caused by one of the NS genes so far reported, but we estimated that this would be 
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unlikely. For example the NEPTUNE study included patients with diseases that we excluded, 
such as IgA nephropathy, membranous nephropathy and secondary FSGS, and found no patients 
in those subgroups with (SRNS) monogenic disease17. 
 
We then used the clinical criteria of steroid resistance (primary, secondary or presumed in the 
congenital/familial cases) or idiopathic NS with FSGS on biopsy as the next level of stratification 
(Figure 3).  
We found 26.2% (49/187) of the cohort has a single gene defect identified by screening the 53 
currently known SRNS genes. By focusing on patients with no single gene defect identified, 
13.8% of the cohort (25/181, Figure 3) have secondary steroid resistance and are highly likely 
to have CFD26 (see below), and 59.7% (108/181) are in an ‘unknown’ category, with either an as 
yet undiscovered gene mutation, or CFD, or possibly a mechanism not yet suspected. This 
means that a maximum of 73.5% of patients could have CFD, although clearly more new genes 
are likely to be ascribed as pathogenic in the future to explain a proportion of this group. The 
risk in the ‘genetic testing negative’ subgroup of a 53.5% post-transplant recurrence risk could 
imply that CFD accounts for at least 53.5% of this group overall. However, this assumes no bias 
towards CFD in the group that has progressed to renal replacement. 
We have previously shown that patients with secondary steroid resistance who reach 
established renal failure have a 90% chance of post-transplantation recurrence, the strongest 
indicator of circulating factor disease.18 This suggests that targeting selected patients earlier in 
their disease for intense immunosuppression may be beneficial, and a trial of for example pre-
transplant plasma exchange in targeted patients could be designed. 
The presumption that most genetic SRNS does not respond to immunosuppression is not 
proven, though potentially strengthened by this study.  This needs further information from 
extended cohorts, as there are case reports of patients with a genetic mutation who have 
responded to steroids, at least partially (e.g. PLCe1, EMP2, TRPC6)19,20. Since some genetic SRNS 
may respond, the question of whether response to secondary immunosuppression such as 
calcineurin inhibitors indicates a non-genetic disease remains open, and is a longer term aim of 
this cohort to address. Longitudinal correlation of proteinuria with medication history may be 
required to distinguish natural variations in glomerular protein leak as well as response to 
angiotensin converting enzyme inhibitors/receptor blockers (ACEi/ARBs). 
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We propose a robust filtering strategy (supplementary Methods) which has the ability to detect 
both known and novel variants according to clinically established criteria.  We have highlighted 
the potential for detecting large deletions using exome sequencing data, which is confirmed by 
customised MLPA analysis, and should be considered at least in all patients in whom a single 
pathogenic variant (in a recessive gene) is found. 
We propose that using a precision medicine approach of clinical phenotyping combined with 
deep sequencing, for patients with INS is a clinically actionable first step towards stratification 
into mechanistic groups in which response to immunosuppression, rate of progression to ESRF 
and risk of post-transplant recurrence can be quantified. This is of benefit to the refinement of 
focused clinical management and could be used to counsel patients/parents regarding 
prognosis. Furthermore, this level of stratification should be used to guide interventional 
clinical trial inclusion criteria, to target the most appropriate mechanistic patient groups. 
 
Material and Methods 
Between 2011 and 2015 we recruited patients with idiopathic nephrotic syndrome, with 
primary, secondary (defined as complete initial steroid response but during subsequent relapse 
no response to 4 weeks oral steroids) steroid resistance or familial NS. We excluded all those 
with a likely secondary glomerulonephritis either histologically (e.g. membranous nephropathy, 
IgA nephropathy, lupus nephritis), or clinically (e.g. diabetic nephropathy, obesity related 
glomerulopathy).6   
Patients 
Our cohort of paediatric SRNS cases was recruited via The United Kingdom Registry for Rare 
Kidney Diseases (RaDaR) and includes all tertiary paediatric nephrology centres in the UK. 
Detailed phenotypic information was entered online (www.renalradar.org), and laboratory data 
is automatically populated via links to the UK Renal Registry (www.renalreg.org). Appropriate 
informed consent from parents/carers is collected and assent from children for collection of 
data and genetic analysis obtained.  The study was approved by the South West research ethics 
committee and institutional review board at each recruiting centre. 
Inclusion criteria for paediatric patients to enter RaDaR (Table 2) included: Primary Steroid 
resistance, Congenital/Familial Nephrotic Syndrome (CNS) (presumed steroid resistance), 
secondary steroid resistance or FSGS on biopsy. Patients with syndromic proteinuric 
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nephropathy were also included. Patients with secondary NS (such as lupus nephritis or 
hypertension) were excluded. Recruited patients were entered onto RaDaR 
(www.renalradar.org) as described previously.6         
Exome Sequencing  
DNA from peripheral blood was extracted (Academic Renal Unit, Bristol) using either QIAamp 
DNA Blood Mini Kit or Gentra Puregene Blood Kit (Qiagen).  Library preparation, sequencing 
and data generation was performed in the Genomics Core Facility of the Biomedical Research 
Centre at Guy’s and St Thomas’ Hospitals and King’s College London. Mapping statistics are 
shown in Table S1, more detailed methods on variant calling are included in supplementary 
material. 
Criteria for inclusion of variants as disease causing (full criteria are provided in 
supplementary methods) 
Variants were included if: Minor allele frequency (MAF) below 0.01; variants not seen 
previously as homozygotes in any of the control databases; for autosomal dominant genes, 
variants not present in any control database; missense variants needed to be predicted by at 
least 2 in silico tools as potentially deleterious; synonymous and splice site variants were 
considered where there was a consistent predicted splice effect across the majority of tools; the 
amino acid must be conserved and not present in another multicellular organism. 
Analytic Plan 
We aimed to analyse the results of complete genetic testing in two ways. Firstly according to 
primary or secondary resistance (Figure 3), in order to address the hypothesis that secondary 
resistance is a surrogate for immunological disease and carries a high risk of post-transplant 
recurrence and low incidence of monogenic disease. Secondly according to a clinical pathway 
that would be of direct utility to physicians. Therefore we stratified patients into those with 
monogenic disease and those testing negative, then further separated according to primary or 
secondary steroid resistance. The categories are then presented according to clinical features 
pre-transplant, and risk of recurrence.   
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Figure and table legends 
Table 1. 53 Genes associated with steroid-resistant nephrotic syndrome (SRNS) of congenital, childhood, or 
adult onset.5-7,10,21-23 Genes with a likely or known mutation, or a risk allele, found in this cohort are highlighted in 
grey. 
FSGS: Focal segmental glomerulosclerosis. CNS: congenital nephrotic syndrome. NS: nephrotic syndrome. SRNS; 
Steroid resistant nephrotic syndrome, SSNS – Steroid Sensitive Nephrotic Syndrome, SDNS – steroid dependent NS; 
DMS – diffuse mesangial sclerosis; AD – autosomal dominant, AR – autosomal recessive, DMS - Diffuse mesangial 
sclerosis, MPGN - Membranoproliferative glomerulonephritis, ESRD – End stage renal disease.  
Table 2. Clinical criteria for inclusion 
NS – nephrotic syndrome, FSGS – focal segmental glomerulosclerosis, SRNS – steroid resistant NS, SLE - systemic 
lupus erythematosus, HSP - Henoch-Schonlein purpura, MPGN - membranoproliferative glomerulonephritis, HIVAN - 
HIV-associated nephropathy. 
Table 3. Summary of clinical details.  
FSGS-Focal segmental glomerulosclerosis, MCD-Minimal Change Disease, MHc-Mesangial hypercellularity, DMS-
Diffuse mesangial sclerosis, ESRF-End stage renal failure, GBM: glomerular basement membrane, *included because 
FSGS on biopsy or CNS 
Table 4. Known and potential mutations in the 49 patients with monogenic nephrotic syndrome  
 (H) -  homozygote, (Hemi) – hemizygote,  F – familial, DP - disease associated polymorphism, SRNS - Steroid 
Resistant Nephrotic Syndrome, DMS - Diffuse mesangial sclerosis, aHUS - atypical Haemolytic uraemic syndrome, 
SIFT, MT and splicing predictions from Alamut, p – paternal, m – maternal, l - low risk, m - medium risk, NS - 
Nephrotic Syndrome, h - high risk, Y – deleterious, Na - not applicable, MT – MutationTaster, ExAC  –  The Exome 
Aggregation Consortium (http://exac.broadinstitute.org/), pos – This TRPC6 variant is considered possibly 
pathogenic here,  a - patient included in24, b - patient included in8, c - patient included in9, d - patient included in10, e – 
c.378+5G> 25, patients 26 and 27 are siblings, patients 45,46 and 47 are siblings.  Using Alamut Visual 2.7 
(SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, Human Splicing Finder) variants were considered likely 
pathogenic where there was a consistent predicted splice effect across the majority of tools. 
Figure 1. Kaplan-Meier plot showing percentage of kidney survival in the genetic and genetic mutation 
negative group of patients. 
Demonstrating faster rate of progression to End Stage Renal Failure (ESRF) in genetic vs. non-genetic cases. Log-rank 
(Mantel-Cox) Test (P value <0.0001). 
Figure 2: Breakdown of monogenic causes vs Genetic testing negative patients, according 
to age of onset of disease 
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Figure 3. A precision medicine based guide to investigation of SRNS 
* Patients 36, 88, 122, 160, 164, 187 are steroid sensitive (FSGS on biopsy) or unknown and thus are not included in 
the figure. KDIGO – Kidney Disease Improving Global Outcomes Guidelines. Age of onset of ESRF not known for 
patients 62 and 179 thus n=30 for CKD5 patients and n=28 for mean age of onset of ESRF; Mean age of onset of NS, 
and Mean age of onset of ESRF were compared and the only significant difference (#) was noted for Mean time to 
ESRF between primary+presumed monogenic and primary+presumed non-monogenic/unknown and secondary 
SRNS, with P value 0.0311 (two-tailed unpaired t test). 
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